Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pulmonx (LUNG) EPS (Weighted Average and Diluted) (2020 - 2025)

Pulmonx (LUNG) reported EPS (Weighted Average and Diluted) of -$0.34 for Q3 2025, up 5.56% year-over-year from -$0.32 in Q3 2024, and up 10.53% on a QoQ basis from -$0.38 in Q2 2025.

Pulmonx (LUNG) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.34 in Q3 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 5.56% year-over-year to -$0.34 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.41 (up 4.08% YoY) and the FY2024 annual result came in at -$1.44, up 10.0% from the prior year.
  • EPS (Weighted Average and Diluted) advanced to -$0.34 in Q3 2025 per LUNG's latest filing, from -$0.38 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.28 in Q3 2021 and bottomed at -$0.43 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.36 (2021), against an average of -$0.37.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 94.15% in 2021, while the deepest fall reached 105.02% in 2021.
  • Tracing LUNG's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.36 in 2021, then declined by 5.56% to -$0.38 in 2022, then grew by 5.26% to -$0.36 in 2023, then grew by 8.33% to -$0.33 in 2024, then dropped by 3.03% to -$0.34 in 2025.
  • Per Business Quant, the three latest LUNG EPS (Weighted Average and Diluted) figures stand at -$0.34 (Q3 2025), -$0.38 (Q2 2025), and -$0.36 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.61
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 1.93
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.89
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.90
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.66
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 0.51
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.85
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 2.24
10 Pulmonx 67.30 Mn -2.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 -0.34
Jun 30, 2025 -0.38
Mar 31, 2025 -0.36
Dec 31, 2024 -0.33
Sep 30, 2024 -0.36
Jun 30, 2024 -0.39
Mar 31, 2024 -0.36
Dec 31, 2023 -0.36
Sep 30, 2023 -0.39
Jun 30, 2023 -0.43
Mar 31, 2023 -0.42
Dec 31, 2022 -0.38
Sep 30, 2022 -0.38
Jun 30, 2022 -0.40
Mar 31, 2022 -0.43
Dec 31, 2021 -0.36
Sep 30, 2021 -0.28
Jun 30, 2021 -0.36
Mar 31, 2021 -0.35
Dec 31, 2020 7.17
Sep 30, 2020 -1.37
Jun 30, 2020 -6.15
Mar 31, 2020 -3.76